The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

Tech in AsiaAsia

OpenAI, Moderna expand AI use in drug development

10.19

Before ChatGPT Enterprise, Moderna built an internal tool, mChat, using OpenAI's API.

Read at Tech in Asia ↗

One letter a week, starting soon.

Latest

OpenAI, Moderna expand AI use in drug development

More from Tech in Asia on Accept All

AsiaSG AI cloud provider Aolani eyes Malaysia data center deals Tech in Asia

AsiaBuying AI tools is easy – getting real value is much harder Tech in Asia

AsiaAustralia’s Nextdc flags earnings risk over power delay Tech in Asia

AsiaDeepSeek’s leaner AI model hits Samsung, SK hynix shares Tech in Asia

AsiaCute AI agents need clear boundaries Tech in Asia

AsiaGoTo releases open-source AI model for Indonesian languages Tech in Asia